FDAnews

BIOPARTNERS' BIOSIMILAR DRUG KNOCKED BACK IN EUROPE

BioPartners has failed to bring its second biosimilar product into Europe after the European Agency for the Evaluation of Medicinal Products (EMEA) issued a negative opinion on its hepatitis C drug, citing characterisation, manufacturing and quality control concerns.
In-PharmaTechnologist.com